Cell Cycle/DNA Damage

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC11759	AKCI	A small-molecule inhibitor that blocks the Aurora C/IκBα interaction (IC50=24.9 uM) and exerts antitumor activity in MDA-MB-231 breast cancer cells. More description
DC11716	XL-844	A potent, specific, orally available, ATP‑competitive inhibitor of Chk1 and Chk2 with Ki of 2.2 nM and 0.07 nM, respectively. More description
DC11713	NSC-109555 ditosylate	A potent, selective, reversible, ATP-competitive Chk2 inhibitor with IC50 of 0.2 uM. More description
DC11677	CCT-271850	A potent, selective, orally bioavailable Mps1 kinase inhibitor with IC50 of 11 nM. More description
DC11704	CFI-401870	A potent, selective, orally active Mps1 (TTK) inhibitor with IC50 of 3.1 nM. More description
DC11733	SAR-020106	A potent, selective, ATP-competitive Chk1 inhibitor with IC50 of 13.3 nM. More description
DC11711	VER-158411	A potent, selective, ATP-competitive Chk1 and Chk2 inhibitor with IC50 of 4.4 nM and 4.5 nM, respectively. More description
DC11635	Poloxin-2	A potent, selective PLK1 PBD inhibitor with IC50 of 1.36 uM. More description
DC11710	GDC-0425	A potent, selective and orally active Chk1 inhibitor. More description
DC11717	PD-321852	A potent, reasonably selective Chk1 inhibitor with cell IC50 of 5 nM. More description
DC11714	PV-1019	A potent, ATP-competitive and highly selective Chk2 inhibitor with IC50 of 138 nM. More description
DC11672	G-9791	A potent and selective group I PAK (pan-PAK1/2/3) inhibitor with Ki of 0.95/2 nM for PAK1/2, respectively. More description
DC11654	VRX-0466617	A potent and selective Chk2 inhibitor with Ki/IC50 of 11 nM/120 nM. More description
DC11715	PV-1115	A potent and highly selective Chk2 inhibitor with IC50 of 0.14 nM. More description
DC11800	G1T38 dihydrochloride	A novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively. More description
DC11799	G1T38	A novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively. More description
DC11953	MU 380	A novel potent, selective CHK1 inhibitor 2 nM, >80-fold selectivity over CHK2. More description
DC11888	Arfolitixorin	A novel antifolate modulator compound.. More description
DC11863	CA224	A non-planar analogue of fascaplysin that selectively inhibits CDK4/cyclin D1 with IC50 of 5.5 uM. More description
DC11851	Clitocine	A naturally occurring nucleoside analog that possesses antitumor activity, also is a potent and efficacious readthrough agent. More description
DC11718	Debromohymenialdisine	A marine sponge alkaloid that inhibits Chk1 and Chk2 with IC50 of 3 and 3.5 uM, respectively. More description
DC11779	TNKS-IN-41	A highly potent and selective tankyrase inhibitor with pIC50 of 8.5 and 8.1 for TNKS1 and TNKS2, respectively. More description
DC11932	GPX-150	A doxorubicin analog that demonstrates anti-cancer activity without cardiotoxicity, does not inhibit topoisomerase IIβ activity at 100 uM. More description
DC11874	CDK12 inhibitor E9 racemate	A clinical analog of THZ1 and a selective, covalent CDK12 inhibitor that is not susceptible to ABC transporter-mediated drug efflux. More description
DC11873	CDK12 inhibitor E9 R-isomer	A clinical analog of THZ1 and a selective, covalent CDK12 inhibitor that is not susceptible to ABC transporter-mediated drug efflux. More description
DC8944	5-Fluorouracil	5-Fluorouracil is a potent antitumor agent that affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. More description
DCK-004	corilagin	>98%,Standard References More description
DCZ-158	CALCIUML-5-METHYLTETRAHYDROFOLATE	>98%,Standard References More description

Cell Cycle/DNA Damage

Customized Consultation X

Your information is safe with us. * Required Fields.